Last reviewed · How we verify

NCT07167082: PRO-HAND

Hand Grip Strength and Prognosis in Hospitalized Cancer Patients

Completed Last updated 11 September 2025
What this trial tests

trial testing Hand Grip Strength Measurement in Cancer in 130 participants. Completed in 25 March 2025.

Timeline
1 September 2024
Primary endpoint
20 October 2024
25 March 2025

Quick facts

Lead sponsorAnkara Etlik City Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment130
Start date1 September 2024
Primary completion20 October 2024
Estimated completion25 March 2025
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Ankara Etlik City Hospital

Who can join

18 and older, any sex, with Cancer or Hospitalizations. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective cohort study aims to investigate the relationship between hand grip strength and prognosis in hospitalized cancer patients. Hand grip strength, a simple, rapid, and non-invasive measure of overall muscle function, is increasingly recognized as an indicator of frailty, nutritional status, and physical health. The study will evaluate whether lower hand grip strength is associated with higher short-term mortality (30-day all-cause mortality) and adverse clinical outcomes, including ICU admission, hospital readmission, and functional decline.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Ankara Etlik City Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07167082.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing